Sign In
Last checked at 
13 Apr 2026 12:00
Convatec Group Plc ("Convatec" or "the Company")
Professor Constantin Coussios OBE steps down from
Board of Directors and AGM resolution change
London, UK, 13 April 2026 - Convatec congratulates Professor Constantin Coussios OBE on his appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. He will be stepping down as a Non-Executive Director of Convatec Group Plc with effect from 30 April 2026 as he takes up his new appointment.
Since his appointment in September 2020, Professor Coussios has worked closely with the Board, senior management and Convatec's Chief Science, Innovation & Quality Officer Dr Divakar Ramakrishnan to transform and re-shape Convatec's research and development capabilities, accelerate new product development, and position the Company for sustained, innovation-led growth. Over the past six years, Convatec has completed several transformative strategic acquisitions, its internal new product development cycle time has been compressed by c.30%, and the vitality index has strengthened steadily from c.10% to c.30%, with 16 new product launches underway since 2022.
Dr John McAdam CBE, Chair of the Board, said: "Over the past six years, Constantin has been key to the successful delivery of Convatec's innovation-led turnaround and we thank him for his unique contribution. We now have the strongest pipeline of innovative new products in Convatec's history. As Constantin takes up his exciting new role at the University of Oxford, together with all Board colleagues, we wish him every continued success for the future."
As the Company's AGM Notice has already been issued, the Company confirms that the resolution to re-elect Professor Coussios as a Non-Executive Director of the Company (resolution number 9) is now withdrawn. The withdrawal of resolution number 9 does not otherwise affect the validity of the Notice of Meeting, the proxy form or any proxy votes already submitted on other proposed resolutions. The numbering of all other proposed resolutions at the AGM will remain unchanged.
This announcement is made in accordance with Listing Rule 6.4.6.
Enquiries
Company Secretariat: CoSec@convatec.com
Media: mediarelations@convatec.com
Analysts & investors: ir@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 3.1 Additional regulated information required to be disclosed under the laws of the United Kingdom
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
Follow the stocks
